v3.26.1
Common Stock - Additional Information (Details) - USD ($)
 1 Months Ended 6 Months Ended 12 Months Ended
Oct. 31, 2025
Jun. 30, 2024
Oct. 31, 2021
Apr. 30, 2020
Jun. 30, 2026
Dec. 31, 2025
Class of Stock [Line Items]            
Common stock, shares authorized         300,000,000 300,000,000
Common stock, par value         $ 0.0001 $ 0.0001
Common stock voting rights         one vote per share  
Common stock dividend         $ 0  
Stock Purchase Agreement | CFF | Common Stock            
Class of Stock [Line Items]            
Number of shares sold and issued 776,398          
Issuance of common stock for the offering program, net of issuance costs $ 7,500,000          
Additional investment amount subject to specific clinical milestone and at option of company $ 3,600,000          
Funding Agreement | CFF            
Class of Stock [Line Items]            
Additional funding upon acceptance of investigational New Drug application     $ 4,000,000 $ 4,000,000    
Additional investment in cash     $ 4,000,000      
Funding Agreement | CFF | Common Stock            
Class of Stock [Line Items]            
Number of shares sold and issued     125,715      
Funding Agreement | CFF | Series C Redeemable Convertible Preferred Stock            
Class of Stock [Line Items]            
Investment in redeemable convertible preferred stock financing       $ 10,000,000    
Sales Agreement | Leerink Partners LLC            
Class of Stock [Line Items]            
Number of shares sold and issued         3,518,472 1,175,000
Aggregate net proceeds, after deducting underwriting discounts and commissions and offering costs         $ 31,600,000 $ 9,600,000
Maximum | Sales Agreement | Leerink Partners LLC            
Class of Stock [Line Items]            
Aggregate gross sales proceeds from common stock   $ 250,000,000